These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 1370736

  • 1. IgM and IgG alloantibody responses to MHC class I and II following rat renal allograft rejection. Effects of transplantectomy and posttransplantation blood transfusion.
    Wray DW, Baldwin WM, Sanfilippo F.
    Transplantation; 1992 Jan; 53(1):167-74. PubMed ID: 1370736
    [Abstract] [Full Text] [Related]

  • 2. IgG alloantibody responses to donor-specific blood transfusion in different rat strain combinations as a predictor of renal allograft survival.
    Wasowska B, Baldwin WM, Sanfilippo F.
    Transplantation; 1992 Jan; 53(1):175-80. PubMed ID: 1370737
    [Abstract] [Full Text] [Related]

  • 3. The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses.
    Wasowska B, Baldwin WM, Howell DN, Sanfilippo F.
    Transplantation; 1993 Sep; 56(3):672-80. PubMed ID: 7692630
    [Abstract] [Full Text] [Related]

  • 4. Different patterns of sensitization following renal allograft rejection in an inbred rat strain combination.
    Wray DW, Baldwin WM, Sanfilippo F.
    Transplantation; 1993 May; 55(5):1132-8. PubMed ID: 8497894
    [Abstract] [Full Text] [Related]

  • 5. Association of donor-specific blood transfusion enhancement of rat renal allografts with accelerated development of antiidiotypic antibodies and reduced alloantibody responses.
    Downey WE, Baldwin WM, Sanfilippo F.
    Transplantation; 1990 Jan; 49(1):160-6. PubMed ID: 2301006
    [Abstract] [Full Text] [Related]

  • 6. IgM and IgG alloantibody production by splenocytes and deposition in rat renal allografts are decreased by donor-specific blood transfusion.
    Baldwin WM, Rhoton K, Sanfilippo F.
    Transplantation; 1991 Feb; 51(2):481-5. PubMed ID: 1994544
    [Abstract] [Full Text] [Related]

  • 7. Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection.
    Ruiz P, Coffman TM, Howell DN, Straznickas J, Scroggs MW, Baldwin WM, Klotman PE, Sanfilippo F.
    Transplantation; 1988 Jan; 45(1):1-7. PubMed ID: 3276038
    [Abstract] [Full Text] [Related]

  • 8. Donor-specific cellular immunity in rejecting and long-term-surviving class I-disparate rat renal allograft recipients.
    Ruiz P, Fuller J, Sanfilippo F.
    Transplantation; 1990 Jan; 49(1):175-83. PubMed ID: 2301009
    [Abstract] [Full Text] [Related]

  • 9. The contribution of terminal complement components to acute and hyperacute allograft rejection in the rat.
    Brauer RB, Baldwin WM, Ibrahim S, Sanfilippo F.
    Transplantation; 1995 Jan 27; 59(2):288-93. PubMed ID: 7839453
    [Abstract] [Full Text] [Related]

  • 10. Complement contributes to the rejection of complete and class I major histocompatibility complex--incompatible cardiac allografts.
    Qian Z, Jakobs FM, Pfaff-Amesse T, Sanfilippo F, Baldwin WM.
    J Heart Lung Transplant; 1998 May 27; 17(5):470-8. PubMed ID: 9628565
    [Abstract] [Full Text] [Related]

  • 11. The rejection mechanism of rat pancreaticoduodenal allografts with a class I MHC disparity.
    Yamamoto S, Ito T, Nakata S, Nozaki S, Uchikoshi F, Shirakura R, Kamiike W, Miyata M, Matsuda H.
    Transplantation; 1994 Apr 27; 57(8):1217-22. PubMed ID: 7909966
    [Abstract] [Full Text] [Related]

  • 12. Contrasting outcomes of donor-specific blood transfusion: effectiveness against cell-mediated but not antibody-mediated rejection.
    Yang CP, Shittu E, McManus B, Wood PJ, Bell EB.
    Transplantation; 1998 Sep 15; 66(5):639-45. PubMed ID: 9753346
    [Abstract] [Full Text] [Related]

  • 13. FcR blocking activity in serum of actively enhanced rat renal allograft recipients due to IgG anti-class II MHC alloantibody.
    Marshall HE, Bolton EM, Gracie JA, Cocker JE, Sandilands GP, Bradley JA.
    Immunology; 1990 Mar 15; 69(3):379-84. PubMed ID: 2312162
    [Abstract] [Full Text] [Related]

  • 14. Induction of allograft nonresponsiveness after intrathymic inoculation with donor class I allopeptides. I. Correlation of graft survival with antidonor IgG antibody subclasses.
    Mhoyan A, Cramer DV, Baquerizo A, Shirwan H.
    Transplantation; 1997 Dec 27; 64(12):1665-70. PubMed ID: 9422399
    [Abstract] [Full Text] [Related]

  • 15. Alloantibody and intragraft cellular response to MHC class I-disparate kidney allografts in recipients tolerized by donor-specific transfusion and cyclosporine.
    Tweedle JR, Middleton SE, Marshall HE, Bradley JA, Bolton EM.
    Transplantation; 1996 Jul 15; 62(1):23-9. PubMed ID: 8693538
    [Abstract] [Full Text] [Related]

  • 16. Lack of correlation between the induction of donor class I and class II major histocompatibility complex antigens and graft rejection.
    Wood KJ, Hopley A, Dallman MJ, Morris PJ.
    Transplantation; 1988 Apr 15; 45(4):759-67. PubMed ID: 3282359
    [Abstract] [Full Text] [Related]

  • 17. Chronic renal allograft rejection: the significance of non-MHC alloantigens.
    Duijvestijn A, Vlek L, Duistermaat L, van Rie H, van Breda Vriesman P.
    Transpl Int; 1992 Apr 15; 5 Suppl 1():S639-44. PubMed ID: 14621897
    [Abstract] [Full Text] [Related]

  • 18. Two levels of help for B cell alloantibody production.
    Steele DJ, Laufer TM, Smiley ST, Ando Y, Grusby MJ, Glimcher LH, Auchincloss H.
    J Exp Med; 1996 Feb 01; 183(2):699-703. PubMed ID: 8627185
    [Abstract] [Full Text] [Related]

  • 19. T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity.
    Gracie JA, Bolton EM, Porteous C, Bradley JA.
    J Exp Med; 1990 Dec 01; 172(6):1547-57. PubMed ID: 2258695
    [Abstract] [Full Text] [Related]

  • 20. Peptides derived from alpha-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection.
    Shirwan H, Leamer M, Wang HK, Makowka L, Cramer DV.
    Transplantation; 1995 Feb 15; 59(3):401-10. PubMed ID: 7871571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.